vs
Emergent BioSolutions Inc.（EBS）与STURM RUGER & CO INC（RGR）财务数据对比。点击上方公司名可切换其他公司
STURM RUGER & CO INC的季度营收约是Emergent BioSolutions Inc.的1.0倍（$151.1M vs $148.7M），STURM RUGER & CO INC同比增速更快（3.6% vs -23.6%），Emergent BioSolutions Inc.自由现金流更多（$73.8M vs $12.3M），过去两年STURM RUGER & CO INC的营收复合增速更高（5.1% vs -29.6%）
Emergent BioSolutions是一家总部位于美国马里兰州盖瑟斯堡的跨国专业生物制药企业，公司专注于开发针对传染病及阿片类药物过量的疫苗与抗体疗法，同时还为生物防御领域提供相关医疗设备支持。
鲁格公司（Ruger）是总部位于美国康涅狄格州绍斯波特的枪械制造企业，除总部外，还在新罕布什尔州纽波特、北卡罗来纳州梅约丹以及亚利桑那州普雷斯科特设有生产工厂。公司由亚历山大·麦考密克·斯特姆与威廉·B·鲁格于1949年共同创立，自1969年起公开上市交易。
EBS vs RGR — 直观对比
营收规模更大
RGR
是对方的1.0倍
$148.7M
营收增速更快
RGR
高出27.3%
-23.6%
自由现金流更多
EBS
多$61.5M
$12.3M
两年增速更快
RGR
近两年复合增速
-29.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $148.7M | $151.1M |
| 净利润 | $-54.6M | — |
| 毛利率 | 42.9% | 17.8% |
| 营业利润率 | -18.8% | 2.3% |
| 净利率 | -36.7% | — |
| 营收同比 | -23.6% | 3.6% |
| 净利润同比 | -74.4% | — |
| 每股收益（稀释后） | $-0.95 | $0.22 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EBSRGR
| Q4 25 | $148.7M | $151.1M | ||
| Q3 25 | $231.1M | $126.8M | ||
| Q2 25 | $140.9M | $132.5M | ||
| Q1 25 | $222.2M | $135.7M | ||
| Q4 24 | $194.7M | $145.8M | ||
| Q3 24 | $293.8M | $122.3M | ||
| Q2 24 | $254.7M | $130.8M | ||
| Q1 24 | $300.4M | $136.8M |
净利润EBSRGR
| Q4 25 | $-54.6M | — | ||
| Q3 25 | $51.2M | $1.6M | ||
| Q2 25 | $-12.0M | $-17.2M | ||
| Q1 25 | $68.0M | $7.8M | ||
| Q4 24 | $-31.3M | — | ||
| Q3 24 | $114.8M | $4.7M | ||
| Q2 24 | $-283.1M | $8.3M | ||
| Q1 24 | $9.0M | $7.1M |
毛利率EBSRGR
| Q4 25 | 42.9% | 17.8% | ||
| Q3 25 | 62.8% | 15.1% | ||
| Q2 25 | 52.5% | 3.9% | ||
| Q1 25 | 60.2% | 22.0% | ||
| Q4 24 | 39.4% | 22.8% | ||
| Q3 24 | 54.9% | 18.5% | ||
| Q2 24 | -18.8% | 22.3% | ||
| Q1 24 | 49.2% | 21.5% |
营业利润率EBSRGR
| Q4 25 | -18.8% | 2.3% | ||
| Q3 25 | 33.1% | -2.7% | ||
| Q2 25 | 1.1% | -15.6% | ||
| Q1 25 | 22.5% | 6.2% | ||
| Q4 24 | -4.9% | 7.8% | ||
| Q3 24 | 22.0% | 3.1% | ||
| Q2 24 | -79.9% | 6.9% | ||
| Q1 24 | 13.2% | 5.5% |
净利率EBSRGR
| Q4 25 | -36.7% | — | ||
| Q3 25 | 22.2% | 1.2% | ||
| Q2 25 | -8.5% | -13.0% | ||
| Q1 25 | 30.6% | 5.7% | ||
| Q4 24 | -16.1% | — | ||
| Q3 24 | 39.1% | 3.9% | ||
| Q2 24 | -111.2% | 6.3% | ||
| Q1 24 | 3.0% | 5.2% |
每股收益（稀释后）EBSRGR
| Q4 25 | $-0.95 | $0.22 | ||
| Q3 25 | $0.91 | $0.10 | ||
| Q2 25 | $-0.22 | $-1.05 | ||
| Q1 25 | $1.19 | $0.46 | ||
| Q4 24 | $-0.45 | $0.62 | ||
| Q3 24 | $2.06 | $0.28 | ||
| Q2 24 | $-5.38 | $0.47 | ||
| Q1 24 | $0.17 | $0.40 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $205.4M | $92.5M |
| 总债务越低越好 | $589.7M | — |
| 股东权益账面价值 | $522.6M | $283.8M |
| 总资产 | $1.3B | $342.0M |
| 负债/权益比越低杠杆越低 | 1.13× | — |
8季度趋势，按日历期对齐
现金及短期投资EBSRGR
| Q4 25 | $205.4M | $92.5M | ||
| Q3 25 | $245.5M | $80.8M | ||
| Q2 25 | $267.3M | $101.4M | ||
| Q1 25 | $149.1M | $108.3M | ||
| Q4 24 | $99.5M | $105.5M | ||
| Q3 24 | $149.9M | $96.0M | ||
| Q2 24 | $69.7M | $105.6M | ||
| Q1 24 | $78.5M | $115.3M |
总债务EBSRGR
| Q4 25 | $589.7M | — | ||
| Q3 25 | $693.1M | — | ||
| Q2 25 | $700.0M | — | ||
| Q1 25 | $700.0M | — | ||
| Q4 24 | $700.0M | — | ||
| Q3 24 | $700.8M | — | ||
| Q2 24 | $863.8M | — | ||
| Q1 24 | $909.2M | — |
股东权益EBSRGR
| Q4 25 | $522.6M | $283.8M | ||
| Q3 25 | $582.5M | $279.6M | ||
| Q2 25 | $536.2M | $289.3M | ||
| Q1 25 | $552.7M | $321.5M | ||
| Q4 24 | $482.8M | $319.6M | ||
| Q3 24 | $508.4M | $314.9M | ||
| Q2 24 | $386.3M | $321.5M | ||
| Q1 24 | $663.9M | $332.0M |
总资产EBSRGR
| Q4 25 | $1.3B | $342.0M | ||
| Q3 25 | $1.5B | $342.3M | ||
| Q2 25 | $1.4B | $349.5M | ||
| Q1 25 | $1.4B | $379.0M | ||
| Q4 24 | $1.4B | $384.0M | ||
| Q3 24 | $1.5B | $373.5M | ||
| Q2 24 | $1.5B | $376.7M | ||
| Q1 24 | $1.8B | $385.0M |
负债/权益比EBSRGR
| Q4 25 | 1.13× | — | ||
| Q3 25 | 1.19× | — | ||
| Q2 25 | 1.31× | — | ||
| Q1 25 | 1.27× | — | ||
| Q4 24 | 1.45× | — | ||
| Q3 24 | 1.38× | — | ||
| Q2 24 | 2.24× | — | ||
| Q1 24 | 1.37× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $77.7M | $15.5M |
| 自由现金流经营现金流 - 资本支出 | $73.8M | $12.3M |
| 自由现金流率自由现金流/营收 | 49.6% | 8.2% |
| 资本支出强度资本支出/营收 | 2.6% | 2.1% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $156.8M | $38.5M |
8季度趋势，按日历期对齐
经营现金流EBSRGR
| Q4 25 | $77.7M | $15.5M | ||
| Q3 25 | $-2.3M | $12.9M | ||
| Q2 25 | $106.4M | $14.7M | ||
| Q1 25 | $-11.2M | $11.1M | ||
| Q4 24 | $-79.9M | $20.0M | ||
| Q3 24 | $153.7M | $9.4M | ||
| Q2 24 | $47.5M | $18.7M | ||
| Q1 24 | $-62.6M | $7.3M |
自由现金流EBSRGR
| Q4 25 | $73.8M | $12.3M | ||
| Q3 25 | $-5.7M | $7.0M | ||
| Q2 25 | $103.5M | $9.1M | ||
| Q1 25 | $-14.8M | $10.0M | ||
| Q4 24 | $-81.6M | $16.4M | ||
| Q3 24 | $147.9M | $2.6M | ||
| Q2 24 | $42.9M | $10.1M | ||
| Q1 24 | $-73.4M | $5.6M |
自由现金流率EBSRGR
| Q4 25 | 49.6% | 8.2% | ||
| Q3 25 | -2.5% | 5.5% | ||
| Q2 25 | 73.5% | 6.9% | ||
| Q1 25 | -6.7% | 7.4% | ||
| Q4 24 | -41.9% | 11.2% | ||
| Q3 24 | 50.3% | 2.1% | ||
| Q2 24 | 16.8% | 7.7% | ||
| Q1 24 | -24.4% | 4.1% |
资本支出强度EBSRGR
| Q4 25 | 2.6% | 2.1% | ||
| Q3 25 | 1.5% | 4.6% | ||
| Q2 25 | 2.1% | 4.2% | ||
| Q1 25 | 1.6% | 0.8% | ||
| Q4 24 | 0.9% | 2.5% | ||
| Q3 24 | 2.0% | 5.5% | ||
| Q2 24 | 1.8% | 6.6% | ||
| Q1 24 | 3.6% | 1.3% |
现金转化率EBSRGR
| Q4 25 | — | — | ||
| Q3 25 | -0.04× | 8.15× | ||
| Q2 25 | — | — | ||
| Q1 25 | -0.16× | 1.43× | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.34× | 1.98× | ||
| Q2 24 | — | 2.27× | ||
| Q1 24 | -6.96× | 1.04× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EBS
| Medical Countermeasures MCM Product | $99.2M | 67% |
| Commercial Products Segment | $38.4M | 26% |
| All Other Revenue | $11.1M | 7% |
RGR
| Firearms | $150.6M | 100% |
| Castings | $7.3M | 5% |
